Jump to:
loading...| Preferred Name |
blinatumomab |
| Synonyms |
Blincyto |
| ID |
http://purl.bioontology.org/ontology/MESH/C510808 |
| altLabel |
Blincyto antibody MT-103 MEDI-538 MT-103 antibody |
| cui |
C3864946 C3853840 C4276437 C3853839 |
| HM |
D018033 |
| Inverse of RB |
4FR53SIF3A 0 |
| isa | |
| LT |
TRD |
| Mapped to | |
| MDA |
20060608 |
| MeSH Frequency |
386 |
| MMR |
20191031 |
| notation |
C510808 |
| PA |
D000970 |
| prefLabel |
blinatumomab |
| SC |
1 |
| Scope Statement |
a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma |
| SRC |
Curr Opin Mol Ther 2006 Feb;8(1):62-8 |
| TERMUI |
T000966286 T724484 T675543 T675544 T000876662 |
| TH |
NLM (2006) NLM (2008) FDA SRS (2013) NLM (2015) USAN (19XX) INN (19XX) NLM (2020) |
| tui |
T116 T129 T121 |
Create New Mapping